
    
      This is a phase I clinical study of individualized neoantigen peptide vaccine combined with
      targeted drugs in the treatment of EGFR mutant non-small cell lung cancer aimed to evaluated
      the safety and immune response of the neoantigen vaccine treatment.
    
  